Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3 (MORPHO)

356 participants randomized post-HCT to gilteritinib or placebo. Overall RFS difference was not statistically significant (HR 0.679, 95% CI 0.459-1.005, two-sided P=0.0518). 50.5% had MRD detectable pre- or post-HCT; in this prespecified subgroup, gilteritinib was beneficial (HR 0.515, 95% CI 0.316-0.838, P=0.0065), while those without detectable MRD showed no benefit (HR 1.213, 95% CI 0.616-2.387, P=0.575). Level 2 (RCT with prespecified MRD subgroup; not MRD-guided randomization).

J Clin OncolPubMed 38471061